Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer. [electronic resource]
Producer: 20180925Description: 840-841 p. digitalISSN:- 1873-7560
- Antibodies, Monoclonal -- adverse effects
- Antineoplastic Agents, Immunological -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Data Interpretation, Statistical
- Humans
- Molecular Targeted Therapy
- Probability
- Research Design -- statistics & numerical data
- Time Factors
- Treatment Outcome
- Urinary Bladder Neoplasms -- drug therapy
- Urothelium -- drug effects
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.